Who
Hany Massarany
Director
Company insider
Files Form 4 as: Director, Biodesix; Director, Accelerate Diagnostics; President and CEO, GenMark Diagnostics; Chief Operating Officer, Ventana Medical Systems.
In numbers
- Trades disclosed
- 212
- Buys
- 7
- Sells
- 71
- Bought
- $540K
- Sold
- $7.6M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 3 May 2005
- Last trade
- 2 Jan 2026
- Last filed
- 6 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —7,484 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —6,354 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —7,484 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —6,354 at $0.00 | filing |
| 1 Jul 2025filed 2 Jul 2025 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —26,368 at $0.00 | filing |
| 1 Jul 2025filed 2 Jul 2025 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Code M | —26,368 | filing |
| 20 May 2025filed 22 May 2025 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —86,477 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —42,010 at $0.00 | filing |
| 5 Nov 2024filed 6 Nov 2024 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Bought | $31K22,500 at $1.37 | filing |
| 28 Jun 2024filed 1 Jul 2024 | Accelerate Diagnosticsoption or derivative | SEC FORM 4 Code M | —4,737 at $0.00 | filing |
| 28 Jun 2024filed 1 Jul 2024 | Accelerate Diagnostics | SEC FORM 4 Code M | —4,737 at $0.00 | filing |
| 29 May 2024filed 30 May 2024 | Accelerate Diagnosticsoption or derivative | SEC FORM 4 Code M | —7,894 at $0.00 | filing |
| 29 May 2024filed 30 May 2024 | Accelerate Diagnostics | SEC FORM 4 Code M | —7,894 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —57,246 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —37,050 at $0.00 | filing |
| 20 May 2024filed 21 May 2024 | Accelerate Diagnosticsoption or derivative | SEC FORM 4 Code A | —66,667 at $0.00 | filing |
| 23 Jan 2024filed 25 Jan 2024 | Accelerate Diagnosticsoption or derivative | SEC FORM 4 Code P | —16,666 | filing |
| 23 Jan 2024filed 25 Jan 2024 | Accelerate Diagnostics | SEC FORM 4 Bought | —16,666 | filing |
| 1 Jan 2024filed 3 Jan 2024 | BDSX Biodesixoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —105,389 at $0.00 | filing |
| 3 Aug 2023filed 7 Aug 2023 | BDSX BiodesixDiagnostics & Labs | SEC FORM 4 Code A | $50K30,864 at $1.62 | filing |
News
Biodesix Targets 2028 Availability for AI-Assisted Lung Nodule Imaging TestBDSX · econotimes.com · 19 Oct 2026Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging BiomarkersBDSX · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Hany Massarany; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.